Investigating how temperature-sensitive p53 mutants can fight cancer
Anti-tumor potential of temperature-sensitive p53 mutants
This study is looking at a way to help cancer patients whose tumors have a faulty p53 protein by using cool temperatures to make the cancer cells die or stop growing, and they want to see if this works better when combined with chemotherapy to shrink tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-11032033 on NIH RePORTER |
What this research studies
This research focuses on the p53 tumor suppressor, which is often mutated in cancer, leading to its inactivation. The study aims to rescue the function of these mutant p53 proteins by using a method that induces hypothermia in tumor cells, potentially triggering cell death or halting the cell cycle. By testing this approach in mouse models, researchers hope to evaluate the effectiveness of combining temperature-sensitive p53 activation with chemotherapy to shrink tumors. The ultimate goal is to develop a new treatment strategy for cancers with specific p53 mutations.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients whose tumors harbor temperature-sensitive p53 mutations.
Not a fit: Patients with tumors that do not express temperature-sensitive p53 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative cancer therapies that specifically target tumors with temperature-sensitive p53 mutations.
How similar studies have performed: Preliminary experiments have shown promising results in similar approaches, indicating potential for success in this novel treatment strategy.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Chen, Jiandong — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Chen, Jiandong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.